Time of infliximab therapy initiation and dose escalation in Crohn’s disease

Table 1 Baseline clinical characteristics of cohort n (%)

Variable	All patients (n = 68)
Male	33 (49)
Age at diagnosis1 (yr)	18 (27)
< 17	43 (64)
17-40	6 (9)
> 40
Age at diagnosisa (yr)	24.7 ± 11.9
Past and current smoking2	17 (25)
Age at first infliximab infusion (yr)	34.8 ± 14.8
Disease behavior3	29 (44)
Non-stricturing, non-penetrating	12 (18)
Stricturing	12 (18)
Penetrating	13 (20)
Penetrating (perianal)
Years between diagnosis and therapy initiation1	7.0 (2.0-14.5)
Years between diagnosis and therapy initiation1	13 (19)
< 2 yr	54 (81)
≥ 2 yr
Concurrent immunosuppressant therapy1	34 (51)
Concurrent prednisone therapy3	8 (12)
< 20 mg/d	10 (15)
≥ 20 mg/d
Dose escalation	34 (50)
Mean time to dose escalation (mo)	10.0 (5.3-4.8)

Continuous data are reported as mean ± SD, or median and IQR when not normally distributed.

¹Data for one patient are missing;

²Data for two patients are missing;

³Data unknown for 12 patients. Past smokers defined as those who had quit smoking at least 6 mo prior to first infliximab dose or those who smoked < 5 cigarettes/d. Current smokers defined as those who smoke at least 5 cigarettes/d for at least 6 mo prior to the first dose of infliximab.